Core Insights - On November 14, 2025, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 5.848 billion, 4.746 billion, and 3.666 billion respectively [1][2] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) also ranked as the top three, with trading amounts of 3.081 billion, 2.539 billion, and 2.255 billion respectively [1][2] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Hong Kong Stock Connect)**: - Alibaba-W (09988): Trading amount of 5.848 billion, net inflow of 1.327 billion - Tencent Holdings (00700): Trading amount of 4.746 billion, net inflow of 1.071 billion - SMIC (00981): Trading amount of 3.666 billion, net inflow of 0.664 billion - Xiaomi Group-W (01810): Trading amount of 1.866 billion, net inflow of 0.671 billion - Xpeng Motors-W (09868): Trading amount of 1.262 billion, net inflow of 0.256 billion [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)**: - Alibaba-W (09988): Trading amount of 3.081 billion, net inflow of 0.930 billion - SMIC (00981): Trading amount of 2.539 billion, net inflow of 0.140 billion - Tencent Holdings (00700): Trading amount of 2.255 billion, net inflow of 1.097 billion - Xiaomi Group-W (01810): Trading amount of 1.382 billion, net outflow of 0.604 billion - Sanofi (01530): Trading amount of 0.972 billion, net outflow of 0.178 billion [2]

Core Insights - The Hong Kong Innovative Drug ETF (159567) closed down 1.12% with a trading volume of 2.214 billion yuan on November 14, 2024 [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of November 13, 2024, the fund's latest share count was 9.665 billion shares, with a total size of 8.579 billion yuan, reflecting a year-to-date increase of 2344.51% in shares and 2170.81% in size [1] Fund Performance - The current fund manager, Ma Jun, has achieved a return of 69.74% since taking over on January 3, 2024 [2] - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant weightings in the portfolio [2] Trading Activity - Over the past 20 trading days, the ETF has accumulated a trading volume of 28.057 billion yuan, averaging 1.403 billion yuan per day [1] - Year-to-date, the ETF has recorded a total trading volume of 251.214 billion yuan, with an average daily trading volume of 1.196 billion yuan [1]

Core Insights - The Hong Kong stock market saw a net inflow of 12.887 billion HKD from northbound trading on November 14, with the Shanghai-Hong Kong Stock Connect contributing 7.273 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 5.614 billion HKD [1] Group 1: Top Net Buyers - Alibaba-W (09988) received a net inflow of 13.27 billion HKD, with a total trading volume of 58.48 billion HKD, comprising 35.87 billion HKD in buying and 22.61 billion HKD in selling [2] - Tencent (00700) saw a net inflow of 10.71 billion HKD, with total trading of 47.46 billion HKD, consisting of 29.08 billion HKD in buying and 18.38 billion HKD in selling [2] - SMIC (00981) had a net inflow of 6.64 billion HKD, with total trading of 36.66 billion HKD, including 21.65 billion HKD in buying and 15.01 billion HKD in selling [2] Group 2: Company-Specific Developments - Alibaba is reportedly launching the "Qianwen" project, an AI assistant app aimed at competing with ChatGPT, which has already seen significant application during the Double Eleven shopping festival [4] - Tencent's third-quarter performance exceeded expectations, driven by growth in advertising and gaming, with potential increases in AI spending to enhance long-term growth prospects [5] - SMIC reported a third-quarter revenue of 2.4 billion USD, reflecting a year-on-year growth of 10% and a quarter-on-quarter growth of 8%, surpassing market expectations [5] - XPeng Motors (09868) received a net inflow of 4.67 billion HKD, with expectations of profitability in Q4 and significant growth driven by AI initiatives [6] Group 3: Top Net Sellers - China Life (02628) experienced a net outflow of 2.61 billion HKD, while China Mobile (00941) saw a net outflow of 579.6 million HKD [7] - Three Life Pharmaceuticals (01530) faced a net outflow of 1.74 billion HKD, with recent developments in clinical trials for its innovative drugs [7]

Market Overview - The Hang Seng Index closed at 27,073, up 0.56% for the day and 34.96% year-to-date[3] - The Hang Seng Technology Index rose by 0.80% to 5,981, with a year-to-date increase of 33.87%[3] - The Hang Seng China Enterprises Index increased by 0.68% to 9,599, showing a year-to-date growth of 31.68%[3] Sector Performance - Major technology stocks showed mixed results; Alibaba rose over 3% following news of a rebranding to enhance AI recognition[9] - The paper industry saw significant gains, with Nine Dragons Paper up over 10% due to a price increase of 30-100 RMB per ton[9] - The innovative drug sector was active, with 3SBio rising over 10% and BeiGene up over 7% after reporting a net profit of 1.139 billion RMB for Q3[9] Commodity and Energy Markets - Lithium battery stocks surged, with Ganfeng Lithium increasing over 12% as lithium carbonate futures rose 20% since mid-October[9] - Gold stocks collectively strengthened, with China Silver Group up over 12% as spot gold prices surpassed $4,220 per ounce[9] - OPEC warned of a "structural surplus" in the global oil market, leading to a decline in international oil prices[9] U.S. Market Trends - U.S. major indices closed lower, with the S&P 500 down 1.65% and the Nasdaq down 2.29% amid concerns over interest rate cuts[9] - Large tech stocks mostly fell, with Nvidia down 3.58% and Amazon down 2.71%[12] - The market's sentiment was pressured by Fed officials expressing hesitance on further rate cuts, reducing the probability of a December cut to nearly 50%[9] Japanese Market Insights - The Nikkei 225 index rose 0.43%, supported by a rebound in investor sentiment following the end of the U.S. government shutdown[12] - The Producer Price Index (PPI) in Japan increased by 2.7% year-on-year, exceeding market expectations[12] - Bank stocks in Japan generally strengthened, with Mitsubishi UFJ Financial Group up 2%[12]

消息面上，三生制药在2025年STIC会议上公布707联合化疗治疗1LNSCLC的临床2期研究数据。此外， 辉瑞公布707全球临床策略，辉瑞与三生制药达成协议后，积极推进707的临床开发，并将707管线列为 其核心管线，目前已经提交5个新的临床申请，辉瑞的第二波开发计划预计在2026年底前将新增10个适 应症的临床试验和10种以上新型组合方案。 三生制药(01530)再涨近5%，截至发稿，涨4.03%，报35.14港元，成交额11.29亿港元。 华泰证券此前发布研报称，10月30日，根据Clinicaltrials披露，辉瑞注册了PF-08634404（SSGJ-707）的 两项全球三期临床试验（NSCLC和CRC），正式启动海外临床。该行认为辉瑞707全球临床开展速度超 市场预期，充分体现了FDA对中国创新药的认可，随着ADC联用等后续临床的逐步开展，有望持续催 化公司估值提升。 ...

华泰证券此前发布研报称，10月30日，根据Clinicaltrials披露，辉瑞注册了PF-08634404(SSGJ-707)的两 项全球三期临床试验(NSCLC和CRC)，正式启动海外临床。该行认为辉瑞707全球临床开展速度超市场 预期，充分体现了FDA对中国创新药的认可，随着ADC联用等后续临床的逐步开展，有望持续催化公 司估值提升。 消息面上，三生制药在2025年STIC会议上公布707联合化疗治疗1LNSCLC的临床2期研究数据。此外， 辉瑞公布707全球临床策略，辉瑞与三生制药达成协议后，积极推进707的临床开发，并将707管线列为 其核心管线，目前已经提交5个新的临床申请，辉瑞的第二波开发计划预计在2026年底前将新增10个适 应症的临床试验和10种以上新型组合方案。 三生制药(01530)再涨近5%，截至发稿，涨4.03%，报35.14港元，成交额11.29亿港元。 ...

Core Viewpoint - Hong Kong pharmaceutical stocks are showing resilience, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 1.12%, indicating a strong performance in the sector [1] Industry Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has experienced a three-day upward trend, with leading stocks such as Cloudtop New Drug, 3SBio, and InnoCare Pharma driving the gains [1] - The Hang Seng Innovative Drug ETF (159316) has seen trading volumes exceed 500 million yuan, reflecting increased investor interest and market activity [1] - The A-share pharmaceutical commercial sector is also performing well, with the E Fund Innovative Drug ETF (516080) index rising nearly 1% in early trading [1] Industry Trends - According to CICC, there is a clear trend of innovation going global, with ongoing benefits from drug review reforms and supportive policies in China [1] - The Chinese innovative drug industry is transitioning into its 2.0 era, moving from "importing and imitating" to "innovating and exporting" [1] - The industry is increasingly internationalizing through models such as License-out and New-Co, showcasing the global ambitions of Chinese innovative drug companies [1] Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first index with 100% "purity" in tracking innovative drugs, providing a precise reflection of the overall performance of Chinese innovative drug companies [1] - The Hang Seng Innovative Drug ETF (159316) is currently the only product tracking this index, offering investors a convenient way to capitalize on industry development opportunities [1]

Core Insights - The 2025 China Medical Insurance negotiation has concluded, with the new commercial insurance innovative drug directory set to be implemented on January 1, 2026, featuring 24 out of 121 submitted innovative drugs [3][4]. - The launch of the commercial insurance innovative drug directory marks a significant milestone for China's innovative drug sector, accelerating clinical applications and laying a solid policy foundation for future national plans [3][4]. - The new round of major national projects aims to establish China as a global center for new drug creation and a hub for the biopharmaceutical industry by 2035 [4]. Industry Trends - 2025 is anticipated to be a landmark year for China's innovative drugs, with 50 innovative drugs approved in the first three quarters alone, surpassing the total for 2024 [5]. - Major licensing deals have been signed, including a $1.97 billion agreement between Heng Rui Medicine and Merck, and a $12.5 billion deal with GlaxoSmithKline [5]. - The A-share and Hong Kong stock markets have seen a surge in innovative drug listings and stock price increases, setting new records [5]. Policy and Regulatory Environment - The "14th Five-Year Plan" explicitly supports innovative drugs and medical devices, indicating a strong governmental push for the sector [5]. - The upcoming implementation of stricter regulations for traditional Chinese medicine is expected to drive high-quality development and improve the supply chain [13]. Market Dynamics - The medical device sector has not experienced the anticipated market performance despite new policies aimed at supporting high-end medical devices [11][14]. - The medical device market is under pressure due to factors such as inventory levels and centralized procurement policies, which have affected performance [11][14]. Future Outlook - The innovative drug sector is expected to remain at the forefront globally for the next 5-10 years, driven by strong R&D capabilities and competitive advantages [7][20]. - Emerging technologies, such as non-invasive brain-computer interfaces, are nearing commercialization, with significant developments expected in 2026 [18][19]. - High-value consumables are projected to see accelerated growth in 2026, benefiting from easing centralized procurement policies [16][17]. Investment Considerations - For innovative drug companies, key indicators to monitor include R&D progress, clinical data, and licensing agreements, which reflect global competitiveness [21][22]. - In the medical device sector, performance metrics such as sales revenue and procurement data will be crucial for assessing future growth potential [22].

Core Viewpoint - The expectation for a Federal Reserve interest rate cut in December has diminished, leading to significant adjustments in key indices of A-shares and Hong Kong stocks, while the Hang Seng Biotechnology Index experienced a rapid rebound [1] Group 1: Market Performance - The Hang Seng Biotechnology Index, launched by the Hang Seng Index Company in 2019, reflects the overall performance of the biotechnology sector in the Hong Kong stock market [1] - The index not only focuses on innovative drugs but also incorporates upstream CXO companies, providing a more comprehensive view of the entire innovative drug industry chain [1] - Notable stocks leading the index's performance include Kingsoft Biotech, JD Health, Hansoh Pharmaceutical, and 3SBio [1] Group 2: Derivative Products - The Hong Kong Stock Exchange announced plans to launch futures for the Hang Seng Biotechnology Index on October 14, 2023, enhancing its expanding ecosystem of derivative products [1] - The new futures contract is set to begin trading on November 28, 2025, offering investors precise risk management tools [1] - The Hang Seng Biotechnology Index is the only index in the Hong Kong pharmaceutical and healthcare sector that has index futures available [1]

| 表情序长 | 大股票理事 動畫行政人員名 作出技霸的 圓人 / 蒙出或接及的 母版的平均價 | | 持有機量的股份數目 佔已發行的 有關事件的日 相關注體股份優媒證權益 | | --- | --- | --- | --- | | .. 1980 11 | | 投分數目 | 【靖奇卿上班 * 在 | | CARDER CONSULTION CO | | 11 11 21 2 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | STATISTICS COLLECTION OF CLAIMS OF THE FOR CANDRE PORT POST A THE CONSULTION CONSULTI CLASSE | | CS20251113E00042 汇资量基金管理股份有限公司 1101(L) | | 1.471.000(L | HKD 28 4000 146,880,000(L) 6,04(L)10/11/2025 C (r) Michi | 格隆汇11月14日丨根据联交所最新权益披露资料显示，2025年11月10日，三生制药( ...